✦ LIBER ✦

Re-Treatment of Relapsed Indolent B-Cell Lymphoma With Rituximab

✍ Scribed by Tadahiko Igarashi; Tomoko Ohtsu; Hirofumi Fujii; Yasutsuna Sasaki; Yasuo Morishima; Michinori Ogura; Yoshitoyo Kagami; Tomohiro Kinoshita; Masaharu Kasai; Yoshio Kiyama; Yukio Kobayashi; Kensei Tobinai; Members of the IDEC-C2B8 Study Group

Publisher: Carden Jennings Publishing
Year: 2001
Tongue: English
Weight: 117 KB
Volume: 73
Category: Article
ISSN: 0925-5710
DOI: 10.1007/bf02981940

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Successful treatment of relapse of an in

Successful treatment of relapse of an intravascular B-cell lymphoma with rituximab-CHOP polychemotherapy

✍ István Takács; N. Erős; I. Bene; F. Bozsó; L. Tordai; Z. Károlyi; G. Radványi; A 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 96 KB

Rituximab retherapy in patients with rel

Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphoma

✍ Andrea Borgerding; Justin Hasenkamp; Bertram Glaß; Gerald Wulf; Lorenz Trümper 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 204 KB

Successful treatment of isolated cutaneo

Successful treatment of isolated cutaneous relapse of follicular lymphoma with rituximab

✍ A. Ferrer; A. López-Guillermo; S. Montoto; T. Estrach; L. Colomo; E. Montserrat 📂 Article 📅 2001 🏛 Springer 🌐 English ⚖ 43 KB

Treatment of B-cell non-Hodgkin's lympho

Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab

✍ Stefano Sacchi; Massimo Federico; Giuseppe Dastoli; Claudia Fiorani; Giovanni Vi 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 232 KB

Rituximab is a chimeric anti CD-20 monoclonal antibody containing human IgG1 kappa constant regions, with murine variable regions. The anti-lymphoma effects of Rituximab are probably due to complement and antibody-dependent cell-mediated cytotoxicity, and induction of apoptosis. Phase II trials have

Bendamustine is effective therapy in pat

Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma : Results from a Multicenter Study

✍ Brad S. Kahl; Nancy L. Bartlett; John P. Leonard; Ling Chen; Kristen Ganjoo; Mic 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 186 KB

Long-term results of gemcitabine plus ox

Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma

✍ Gaetano Corazzelli; Gaetana Capobianco; Manuela Arcamone; Pier Ferruccio Balleri 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 455 KB